Aripiprazole
In brief
- In our pharmacy, you can buy aripiprazole without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Aripiprazole is used for schizophrenia, bipolar I disorder (mania and maintenance). It acts as a partial agonist at dopamine D2 and serotonin 5‑HT1A receptors and an antagonist at 5‑HT2A receptors.
- Usual doses in adults: schizophrenia 10–15 mg once daily (max 30 mg); bipolar mania 15 mg once daily (max 30 mg); start lower and titrate in adolescents, elderly and those with hepatic/renal impairment; depot regimen commonly 400 mg once monthly IM.
- Forms of administration: oral tablets (5, 10, 15, 30 mg), orally disintegrating tablets, oral solution (1 mg/mL) and long‑acting intramuscular depot injections (Abilify Maintena).
- Onset time: some sedative or calming effects may occur within hours to days; symptomatic improvement in psychosis is often seen within 1–2 weeks, with full therapeutic effect developing over several weeks.
- Duration of action: typically once‑daily oral dosing with a plasma half‑life of approximately 75 hours (active metabolite longer), so effects persist for days; long‑acting injectable formulations provide effect for about one month per dose.
- Do not consume alcohol — alcohol increases sedation and dizziness and may worsen other side effects such as orthostatic hypotension.
- The most common side effect is akathisia (restlessness); other frequent effects include insomnia, anxiety, headache, nausea, vomiting, dizziness and somnolence.
- Would you like to try aripiprazole without a prescription?
Basic aripiprazole information
- INN (international nonproprietary name): Aripiprazole.
- Brand names available in the United Kingdom: Abilify; Abilify Maintena; generic suppliers such as Mylan and Neuraxpharm.
- ATC code: N05AX12.
- Forms and dosages: tablets 5mg, 10mg, 15mg, 30mg; orodispersible tablets 10mg, 15mg; oral solution 1mg/mL; long‑acting depot injectables 300mg and 400mg (Abilify Maintena).
- Manufacturers in the United Kingdom: Otsuka (originator, Abilify and Abilify Maintena); generics include Mylan and Neuraxpharm.
- Registration status in the United Kingdom: authorised by the MHRA; prescription-only medicine (POM).
- OTC / Rx classification: Prescription-only medicine (POM).
Legal status and availability in the UK
Aripiprazole is a prescription-only medicine (POM) in the UK.
In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.
What is aripiprazole?
INN, ATC and pharmacological class
Aripiprazole is the International Nonproprietary Name (INN) for this medicine.
The ATC code is N05AX12, classifying it among other antipsychotics.
It acts as a partial dopamine D2 receptor agonist, a partial 5‑HT1A agonist and a 5‑HT2A antagonist, which in simple terms means it balances several brain receptors to reduce psychotic symptoms while often producing less sedation and prolactin elevation than some older drugs.
| Item | Details |
|---|---|
| INN | Aripiprazole |
| ATC code | N05AX12 |
| Mechanism (plain) | Partial D2 agonist; 5‑HT1A partial agonist; 5‑HT2A antagonist |
| Forms | Tablets 5–30mg; ODT 10/15mg; oral solution 1mg/mL; depot 300/400mg |
Licensed indications and standard dosages
Indications and typical UK dosing
Licensed indications include schizophrenia and moderate to severe manic episodes in bipolar I disorder (including prevention of new manic episodes).
Typical adult doses and maximums are listed below and should be tailored to the individual under specialist guidance.
| Indication | Typical adult dose | Paediatric/notes |
|---|---|---|
| Schizophrenia | 10–15mg/day; maximum 30mg/day | Adolescents (15 years and over) start at 10mg; specialist supervision required |
| Bipolar I (mania) | 15mg/day; maximum 30mg/day | Adolescents commonly 10mg/day; adjust with care |
| Long‑acting injectable | 400mg/month IM (Abilify Maintena) | Not for children; initial oral overlap required |
Dose adjustments are recommended for children, elderly patients and those with severe hepatic or renal impairment.
Dosing, administration and missed dose guidance
Oral dosing, ODTs and depot administration
Oral tablets and oral solution can be taken with or without food at a consistent time each day to aid adherence.
Orally disintegrating tablets are placed on the tongue and allowed to dissolve for patients with swallowing difficulty.
Typical initiation uses a low to moderate starting dose with titration over days to weeks depending on indication and tolerability.
For Depot initiation with Abilify Maintena, a 14‑day overlap with oral aripiprazole is required after the first injection to ensure therapeutic levels are reached.
If an oral dose is missed, take it as soon as remembered unless it is nearly time for the next dose, in which case skip the missed dose and continue as normal.
If a depot injection is missed beyond the recommended window (commonly beyond 5–6 weeks), contact the prescriber or clinic for re‑initiation instructions.
| Route | Initiation note |
|---|---|
| Oral tablets/ODT | Start low, titrate to therapeutic dose; consistent daily timing recommended |
| Depot (Abilify Maintena) | Monthly IM injection with 14‑day oral overlap at initiation |
Safety profile: common and serious adverse effects
What to know and monitor
Common adverse effects include akathisia, insomnia, anxiety, nausea, dizziness and somnolence.
Moderate risks include extrapyramidal symptoms such as tremor and rigidity, weight gain and metabolic changes.
Rare but serious risks reported in clinical data include neuroleptic malignant syndrome (NMS) and an increased mortality risk in elderly patients with dementia.
| Common adverse effects | Serious risks |
|---|---|
| Akathisia, insomnia, nausea, dizziness, somnolence | Neuroleptic malignant syndrome, increased mortality in dementia |
| Headache, anxiety | Severe metabolic syndrome, significant EPS |
Monitoring includes baseline and ongoing checks of weight/BMI, blood glucose or HbA1c, lipid profile and blood pressure.
Movement disorder screening and urgent referral are required for signs of NMS: high fever, rigidity and altered mental status.
Contraindications, cautions and interactions
Cautions and interactions
The absolute contraindication is known hypersensitivity to aripiprazole or any component of the product.
Caution is required in elderly patients with dementia due to increased mortality risk, in those with cardiovascular disease, history of seizures, diabetes and severe hepatic or renal impairment.
Drug interactions of note include agents affecting CYP3A4 or CYP2D6 which can alter aripiprazole exposure and drugs that add sedation or raise QT risk when combined with other antipsychotics.
- Interactions: check for strong CYP3A4/2D6 inhibitors or inducers; review other CNS depressants; monitor cardiac risk when co‑prescribing QT‑prolonging medicines.
- When to consult a prescriber: New arrhythmia, seizure history, pregnancy, significant hepatic or renal impairment.
The BNF and specialist advice should guide complex interaction management and dose adjustments.
Starting, titration and switching strategies
Practical regimens for initiation and cross‑titration
Initiation commonly uses a low or moderate starting dose with gradual titration to an effective dose over days to weeks depending on the condition and tolerability.
For schizophrenia, clinicians often aim for 10–15mg/day as an effective range with the ability to increase to 30mg/day if needed.
When switching from another antipsychotic, gradual cross‑titration is advised to reduce the risk of relapse or withdrawal symptoms.
Depot initiation requires oral overlap for 14 days and close coordination with community mental health teams and injection clinics.
- Start → titrate → stabilise → maintain: Begin low, monitor side effects, titrate to response, document and maintain with regular review.
All changes should be managed by the prescribing clinician.
Monitoring, tests and follow‑up
Baseline and ongoing checks for safe use
Baseline checks should include weight/BMI, blood pressure, fasting glucose or HbA1c, lipid profile and, where indicated, ECG and pregnancy testing.
Movement disorder scales may be used to screen for extrapyramidal symptoms at baseline and during follow‑up.
Early monitoring for weight and metabolic change is recommended every three months initially, with a full annual review thereafter.
| Check | Baseline | Ongoing frequency |
|---|---|---|
| Weight/BMI | Yes | 3‑monthly initially |
| Blood glucose / HbA1c | Yes | 3‑monthly if high risk, otherwise annually |
| Lipids | Yes | Annually |
| Movement disorder screening | Yes | At each review |
Red flags such as sudden fever, rigidity, confusion or autonomic instability require urgent referral.
Special populations — children, elderly, pregnancy and comorbidities
Tailored guidance and safety notes
Children and adolescents require lower starting doses and specialist supervision; not all indications are paediatric‑approved.
Elderly patients should start at lower doses and be closely monitored for orthostatic hypotension, somnolence and the increased mortality risk in dementia.
Pregnancy and breastfeeding decisions require a documented risk–benefit discussion and liaison between psychiatry and obstetrics.
Comorbidities such as diabetes, cardiovascular disease and severe hepatic or renal impairment need dose caution and specialist input.
| Population | Adjustment/note |
|---|---|
| Children/Adolescents | Start low, titrate carefully; specialist prescribing |
| Elderly | Lower start dose, monitor for falls and somnolence |
| Pregnancy/Breastfeeding | Individual assessment; obstetric and psychiatric liaison |
| Hepatic/renal impairment | Use caution; severe impairment requires specialist supervision |
Storage and disposal
Safe handling
Tablets should be stored at room temperature, typically 15–30°C, and kept in the original packaging away from moisture.
Injectables such as Abilify Maintena are stored as per the product label, generally 15–30°C and protected from light; do not freeze.
Sharps disposal guidance applies for injectables and unused tablets should be returned via local medicines take‑back schemes or pharmacy collection services.
| Item | Storage condition |
|---|---|
| Tablets | Room temperature 15–30°C; protect from moisture |
| Injectable (Maintena) | Store per label, generally 15–30°C; protect from light; do not freeze |
Alternatives
Choosing between antipsychotics
Alternatives include risperidone, olanzapine, quetiapine, paliperidone, ziprasidone and lurasidone.
Differentiators include metabolic risk (higher with olanzapine), sedative profile (quetiapine more sedating), prolactin elevation (risperidone), and depot availability (paliperidone, risperidone).
| Agent | Key differentiator |
|---|---|
| Risperidone | Higher prolactin risk; depot options exist |
| Olanzapine | Higher metabolic risk |
| Quetiapine | More sedating; useful where insomnia is prominent |
Any switch should be discussed with the prescriber, who will rely on NICE guidance and product information.
Legal status and safety reporting
Reporting and safety alerts
Aripiprazole is a prescription‑only medicine and must be dispensed against a valid prescription.
Suspected adverse events can be reported via the Yellow Card Scheme, and the MHRA publishes recalls and Drug Safety Alerts.
| Action | Where to report / check |
|---|---|
| Report adverse events | Yellow Card Scheme |
| Check recalls and alerts | MHRA and NHS communications |
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 5‑7 days |
| Birmingham | England | 5‑7 days |
| Manchester | England | 5‑7 days |
| Glasgow | Scotland | 5‑7 days |
| Leeds | England | 5‑7 days |
| Liverpool | England | 5‑7 days |
| Bristol | England | 5‑7 days |
| Edinburgh | Scotland | 5‑7 days |
| Sheffield | England | 5‑9 days |
| Cardiff | Wales | 5‑7 days |
| Newcastle upon Tyne | England | 5‑9 days |
| Belfast | Northern Ireland | 5‑9 days |
| Nottingham | England | 5‑9 days |
Key takeaways
Aripiprazole is a widely used antipsychotic with multiple oral formulations and a monthly long‑acting injectable option.
Careful counselling on early akathisia, metabolic monitoring and adherence supports better outcomes.
